Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT02389985 is registered in ClinicalTrials.gov with NewLink Genetics Corporation as lead sponsor.

NCT NCT02389985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02389985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II Study of CRLX101 in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lead sponsor
NewLink Genetics Corporation
Phase
Phase 1/2
Overall status
Terminated
Start date
July 31, 2015
Completion date
October 18, 2018
Enrollment
30 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer